Adamas to Present at Upcoming H.C. Wainwright Conference
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright VIRTUAL BioConnect Conference, being held January 11 – 14, 2021.
A replay of the pre-recorded fireside chat will be available beginning January 11, 2021 in the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. The replay will be available for 30 days.
About Adamas Pharmaceuticals, Inc.
At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.
Contact
|
Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com |
|
Investors: Peter Vozzo Managing Director, Westwicke 443-213-0505 peter.vozzo@westwicke.com |
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
